International IP. Prof. Eric E. Johnson. General Principles

Similar documents
Flexibilities in the Patent System

WIPO NATIONAL WORKSHOP FOR PATENT LAWYERS

Exhaustive Training module for new Patent examiners

372 index. predominantly for supply of domestic market 113, 132 3, 184 5, 186; remedying anticompetitive

WIPO Sub-Regional Workshop on Patent Policy and its Legislative Implementation

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

March 9, H. David Starr. Nath, Goldberg & Meyer

International Patent Regime. Michael Blakeney

Patent examination procedure of Mongolia

What is Intellectual Property?

Topic 5-7. Effective utilization of Patent Classification Systems

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

Where to File Patent Application Yumiko Hamano IP Consultant - IP Commercialization Partner, ET Cube International

Innovation Office. Intellectual Property at the Nelson Mandela University: A Brief Introduction. Creating value for tomorrow

China: Managing the IP Lifecycle 2018/2019

Technology Transfer and Intellectual Property Best Practices

What s in the Spec.?

19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights

Patent Working Requirements Historical and Comparative Perspectives

PROTECTION OF INTELLECTUAL PROPERTY

Finland Russia Ukraine CONTENTS

Topic 8: Filing Patent Applications: Examples of Filing in Different Countries and under the Patent Cooperation Treaty (PCT)

Building a Competitive Edge: Protecting Inventions by Patents and Utility Models

Standing Committee on the Law of Patents

Identifying and Managing Joint Inventions

Protecting your business abroad: Latin America, China and South-East Asia Landscape. Eli Salis 28th February 2017

INTELLECTUAL PROPERTY OVERVIEW. Patrícia Lima

Comments of the AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION. Regarding

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.

An investment in a patent for your invention could be the best investment you will ever

RWANDA EXPERIENCE RUHIMA BLAISE OFFICE OF THE REGISTRAR GENERAL RWANDA DEVELOPEMENT BOARD

Topic 3: Patent Family Concepts and Sources for Family Information

Topic 2: Patent Families

The TRIPS Agreement and Patentability Criteria

UTILITY MODELS A USEFUL NATIONAL STRATEGY FOR PROMOTING INNOVATION?

HISTORY OF PATENT SYSTEM.

Intellectual Property

Patent Examination system in Madagascar. Narisoa RABENJA Technical Manager

WIPO-IFIA INTERNATIONAL SYMPOSIUM ON THE COMMERCIALIZATION OF INVENTIONS IN THE GLOBAL MARKET

PCT System and Its Impact on the Developing Countries

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

CIPO Update. Johanne Bélisle. Commissioner of Patents, Registrar of Trade-marks and Chief Executive Officer

WIPO-WTO Colloquium for Teachers of Intellectual Property

FICPI views on a novelty grace period in a global patent system

Standing Committee on the Law of Patents

The role of IP in economic development: the case of China

Basics of Intellectual Property for Business & Entrepreneurs

Patents as a regulatory tool

PROTECTING INVENTIONS: THE ROLE OF PATENTS, UTILITY MODELS AND DESIGNS

Intellectual Property and Genetic Resources: Relationship with Relevant International Instruments

Key issues in building a strong life sciences patent portfolio. Tom Harding and Jane Wainwright Potter Clarkson LLP

PCT FAQs. Protecting your Inventions Abroad: Frequently Asked Questions About the Patent Cooperation Treaty (PCT)

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

BIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy

Materials for Renewable Energy

Patent Filing Strategy in Hong Kong

IP, STRATEGY, PROCEDURE, FTO Peter ten Haaft (PhD, Dutch and European Patent Attorney)

WIPO LIST OF NEUTRALS BIOGRAPHICAL DATA

Patents and other Intellectual Property. Carl Otto Barth ABACUS Patentanwälte Klocke Späth Barth Adliswil/Zürich (CH) + Horb/Neckar (DE)

Patents and Intellectual Property

WIPO sub-regional workshop on the utilization of. examination capacities and increase the quality of. Kuala Lumpur, Malaysia Nov.29 - Dec.

Realizing Developmental Objectives of The IP System: LDC Priority Needs for Technical and Financial Cooperation Lao PDR Experiences

Intellectual Property Overview

European Patent Law: Law And Procedure Under The EPC And PCT By Ian Muir

A POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA)

Protect your ideas. An introduction to patents for students of natural sciences, engineering, medicine and business administration

A short trip through Trade-related aspects of Intellectual Property Rights (TRIPS) ->START

Tommi Knuutinen INTELLECTUAL PROPERTY RIGHTS

The Patent Cooperation Treaty (PCT) at the center of the international patent system

PCT PROTECTING YOUR INVENTIONS ABROAD: FREQUENTLY ASKED QUESTIONS ABOUT THE PATENT COOPERATION TREATY (PCT) WORLD INTELLECTUAL PROPERTY ORGANIZATION

eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search

PATENTS FOR CHEMICALS, PHARMACEUTICALS AND BIOTECHNOLOGY

Chapter 5 The Fundamentals of the Patent System

University IP and Technology Management. University IP and Technology Management

Standing Committee on the Law of Patents Twenty-Sixth Session

PRACTICE TIPS FOR TRADEMARK PROSECUTION BEFORE THE USPTO

Ref: Overview of the implementation of the TRIPS Agreement (patents) in the EPC contracting states and observer countries

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward


NEW TREATY DEVELOPMENT AND HARMONIZATION OF INTELLECTUAL PROPERTY LAW

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

PCT Related Matters IP Information Roundtable

Yearly Planner for PG Diploma in IPR (PGDIPR)

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

Carnegie Endowment for International Peace

Yearly Planner for 4 th Batch of PG Diploma in IPR (PGDIPR) Course

1. 3. Advantages and disadvantages of using patents as an indicator of R&D output

THE INTERNATIONALIZATION OF PATENT LAWS

Graham McMullin, BA BAI, Ph.D Technology Transfer Case Manager Physical Sciences Trinity Research & Innovation Office

An Essential Health and Biomedical R&D Treaty

Leveraging Intellectual Property for Success

Virtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12:

Statement of. Hon. General J. Mossinghoff Senior Counsel Oblon, Spivak, McClelland, Maier & Neustadt, P.C. before the

Intellectual Property and Public Health - International Framework and Recent Developments in WIPO: SCP and CDIP

11th Annual Patent Law Institute

Topic Engr. Raisa C. Lubina Intellectual Property Rights Specialist II

AAAS Project on Science and Intellectual Property in the Public Interest

A HOLISTIC APPROACH TO TECHNOLOGY LICENSING IN THAILAND

Transcription:

International IP Prof. Eric E. Johnson ericejohnson.com General Principles territoriality Dependence, independence, central attack Procedural harmonization Substantive agreements National treatment Minima 1

International Aspects of Patents territoriality Foreign filing licenses Paris Convention national treatment Patent Cooperation Treaty procedural TRIPS substantive European Patent Convention Foreign Filing Licenses Foreign Filing Licenses To advance national security interests, the Invention Secrecy Act requires for inventions made in the U.S. a foreign filing license, issued by the USPTO, before application can be made to a foreign country. A U.S. patent application is deemed to include an application for a foreign filing license. If the USPTO denies the license, it will issue a secrecy order, in which case the inventor can seek compensation. 2

Paris Convention Paris Convention Convention of Paris for the Protection of Industrial Property of 1884 173 signatories today Cf. 193 internationally recognized sovereign countries Requirements: national treatment, independence of patents, international priority Paris Convention National Treatment Must treat foreign inventors who are nationals of a signatory no worse than domestic inventors E.g.: No higher fees No shorter durations 3

Paris Convention Independence of patents Before the Paris Convention, some countries applied foreign dependence against foreign inventors. Foreign dependence: If any foreign patent expired or was invalidated, the domestic patent was invalidated as well. Effect of independence: Victories and defeats in the courts of one country have no effect on validity in other countries Paris Convention International Priority If a patent application is filed in any signatory, all subsequent applications in other signatories within one year are given priority back to the first-country filing date. In the U.S., per 119(a), foreign applicants get an early constructive filing date for purposes of 102(a) (novelty) and 102(g) (interferences), but not 102(b) (statutory bars). 4

PCT Patent Cooperation Treaty PCT 139 signatories today Procedural Provides a partially internationalized process One international application begins prosecution in all signatories. PCT Filing the International Application First, file an international application Can file this as the first application, or secondarily, claiming priority back based on Paris Convention The international application is treated as if the inventor has filed in all PCT signatories 5

PCT Chapter I proceedings Applicant receives: An international search report, and International Preliminary Report on Patentability Non-binding preliminary examination Includes determination of novelty and nonobviousness based on international principles Next, at applicant s option, proceed to: National stage Chapter II proceedings PCT National stage Elect in which signatories applicant will pursue prosecution, and begin local prosecution Many countries effectively start over at this stage 6

PCT Chapter II proceedings A chance to make amendments and engage in dialogue with examiner before obtaining a second report Used by those who received an unfavorable report under Chapter I Still non-binding EPC European Patent Convention Optional single application and prosecution process through the European Patent Office The European Patent Office can issue patents for all 34 European signatories Not a single European patent, though the phrase European patent is sometimes used A slate of patents, one for each signatory, with legal effect only in that country, under that country s laws. The independence principle applies. 7

TRIPS TRIPS Agreement on Trade-Related Aspects of Intellectual Property Rights Negotiated during the the Uruguay Round of General Agreement on Tariffs and Trade (GATT) in 1994 Covers other IP forms, as well as patent Agreement to TRIPS is a requirement of WTO membership 153 WTO members today Creates substantive minimum standards obligations for national patent laws TRIPS Minimum Standards of TRIPS 20 years from filing date is the minimum term Applicants must provide an enabling disclosure Protectible subject matter: inventions in all fields of technology, provided that they are new, involve an inventive step and are capable of industrial application Exceptions: certain methods of medical treatment, macroorganisms, immoral inventions Pharmaceuticals, not patentable in many countries prior to TRIPS, are not an exception. Judicial review 8

TRIPS Compulsory Licenses Compulsory licenses are essentially not used in the U.S. for inventions. Historically important in other countries, including for pharmaceuticals Substantive limits on countries powers to grant compulsory licenses: Must have made unsuccessful efforts to license Compulsory license must be revocable Remuneration must be adequate Must be predominantly for the domestic market TRIPS TRIPS and Drugs in LDCs TRIPS effectively denies new drugs to poor populations and countries to some extent, including those for large-scale public-health problems such as AIDS, malaria, and other diseases. Despite the downside of TRIPS patent rules, most countries sign TRIPS, as it is required for WTO membership and thus needed for exports. Many smaller, lesser developed countries cannot manufacture pharmaceuticals on their own, so the domestic-market limitation effectively eviscerates the compulsory licensing scheme for them. Many very poor countries have already acceded. Some of the poorest countries have been given an extension until 2016 to implement pharmaceutical patent protection. Exclusive marketing rights ( EMRs ) allow five-year terms of patentlike protection even where implementation is delayed. Mailbox rule or pipeline protection reduces long-term benefit of delayed implementation. While WIPO and developed-countries pressure LDCs to provide monopoly privileges on pharmaceuticals, the WHO is helping LDCs to navigate the red tape to provide cheap generics. 9

TRIPS EEJ Arguments Regarding TRIPS and the Calibrating of Patent Incentives Assuming R&D costs are static, as markets and patent-respecting jurisdictions increase, patent term should decrease. As macro-economic variables become more favorable, and general global wealth increases, patent term should decrease. As non-obviousness thresholds are lowered, patent term should decrease. Certain new fields of technology (software, internet) should have lower patent terms. (Bezos argues this.) TRIPS locks all technical fields and all countries into 20-year patent terms. This causes economic losses. International Aspects of Copyright COPYRIGHT No international copyright The major treaty is the Berne Convention The Universal Copyright Convention was begun by the U.S. as an alternative to Berne. With less stringent provisions, it still applies to some countries not in Berne. TRIPS, NAFTA, and other agreements also concern copyright to some degree. 10

Berne The Berne Convention COPYRIGHT Established 1886 Revised six times, most recently the Paris Revision in 1971 U.S. did not join until March 1, 1989 Requirements: National treatment Certain minima of protection Euro-centric Also called the Berne Union Berne National treatment COPYRIGHT Must treat foreign authors no worse than domestic authors But can treat domestic authors at a disadvantage 11

Berne Minima Under Berne COPYRIGHT Subject-matter: every production in the literary and artistic domain whatever may be the mode or form of its expression Includes architecture Includes compilations and derivatives Does not include news of the day or facts Moral rights Preclusion of formalities Minimum term of life + 50, 50 for anonymous Allows fair use and cover-version compulsory license limitations Berne COPYRIGHT Delayed U.S. Acceptance of Berne Back-door to Berne for U.S. authors Simultaneous publication in the U.S. and Canada Changes to U.S. copyright law for joining: Deletion of notice requirement Deletion of registration requirement Not changed in 1989: Moral rights (deemed covered by unfair competition law) Architectural works Later changes in Berne s spirit Coverage of architectural works Visual Artists Rights Act of 1990 Retroactive protection for foreign works then in the public domain in the U.S. (NAFTA, TRIPS) 12

International Aspects of Trademark Paris Convention Trademark Law Treaty Madrid Agreement and Madrid Protocol TRADEMARK Paris Convention Paris Convention TRADEMARK Procedural Works for trademark registration like it does for patents Priority period is six months instead of one year U.S. is a signatory 13

TLT Trademark Law Treaty TRADEMARK Harmonizes and simplifies application requirements, such as filing requirements, recordation of assignments, physical dimensions of paperwork, etc. U.S. is a signatory Madrid TRADEMARK Madrid Agreement U.S. not a signatory Effectively an international trademark Registration provides automatic protection in all signatories Use not required Allows central attack U.S. objects to because of central attack availability and because American use requirement puts domestic firms at a disadvantage 14

Madrid TRADEMARK Madrid Protocol Eliminates central-attack and userequirement problems to ease U.S. entry into Madrid framework. Effective in the U.S. in November 2003. Forms of IP Not Recognized in the U.S. Database protection Geographical indications Non U.S. forms 15

Geographical indications Non U.S. forms Not recognized in the U.S. Well used in Europe Allows a monopoly for appellations of geographic origin Monopoly privileges inure to a place (not a firm, as with TM) Examples: Champagne (a.k.a. sparkling wine ) Parmesan cheese Geographical indications Non U.S. forms Not recognized in the U.S. Well used in Europe Allows a monopoly for appellations of geographic origin Monopoly privileges inure to a place (not a firm, as with TM) Examples: Champagne (a.k.a. sparkling wine ) Parmesan cheese Might be protected in the U.S. as collective marks or certification marks, if not currently generic 16

WIPO WIPO Building, Geneva WIPO 17